Will a GLP-1 work for me? A clinician’s framework

GLP-1 therapy is not a universal solution, and clinicians who claim it is are not being honest with you. It is a useful tool for a defined subset of adults whose metabolic and behavioral profile makes the mechanism likely to help. The clinician’s job — and the point of an eligibility review that is more than a BMI calculator — is to identify whether you are in that subset. Compounded GLP-1 is compounded under section 503A of the FD&C Act; compounded GLP-1 is NOT FDA-approved as a finished product, and it may support weight management for eligible adults under clinician supervision rather than guaranteeing an outcome for anyone.

The starting filter: BMI and comorbidity

The conventional clinical thresholds for considering pharmacotherapy for weight management in adults are a body mass index of 30 or higher on its own, or a BMI of 27 or higher paired with at least one weight-related comorbidity. Those thresholds were established with finished branded products in major clinical trials and they remain the standard reference clinicians use, including in telehealth.

Comorbidities that count, and that a Form clinician will ask you about directly, include:

• Type 2 diabetes or prediabetes (A1c, fasting glucose history).
• Hypertension, whether treated or untreated.
• Dyslipidemia — high LDL, high triglycerides, low HDL.
• Obstructive sleep apnea, especially if a sleep study is on file.
• Non-alcoholic fatty liver disease.
• Polycystic ovary syndrome with insulin-resistance pattern.
• Osteoarthritis aggravated by weight, particularly knee or hip.

A patient at BMI 28 with PCOS and prediabetes is a stronger candidate than a patient at BMI 30 with no metabolic comorbidities at all. Comorbidity is not a tie-breaker; it is part of the clinical rationale.

The exclusions that do not move

Some histories make GLP-1 therapy inappropriate regardless of how well other criteria fit. These are the screening questions a responsible clinician will not skip:

• Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN-2).
• History of pancreatitis.
• Current or planned pregnancy, or breastfeeding.
• Active or recent eating disorder pathology, particularly purging behaviors.
• Severe documented gastroparesis or other significant motility disorder.
• Type 1 diabetes (not a primary indication; complex co-management).
• Hypersensitivity to GLP-1 receptor agonists.

Behavioral readiness: the part patients skip

The clinical literature on GLP-1 therapy is clear that the medication is a tool to be used alongside nutrition, movement, and sleep — not in place of them. Patients who treat the injection as the entire treatment plan tend to plateau earlier, regain more after stepping off, and feel worse during therapy. Behavioral readiness is not a gating exam, but it is something clinicians assess.

Honest signals of readiness

Patients who do well tend to share a few traits at intake: they understand this is not a quick fix, they can articulate what about their previous attempts did not work, they are willing to eat more protein and drink more water without being reminded weekly, and they have at least a rough plan for how they will eat and move while on therapy. They are not perfect. They are committed.

Signals worth pausing on

If your honest answer to “why now?” is that you saw a TikTok and want to lose 20 pounds before a wedding next month, that is not necessarily disqualifying — but it is a conversation worth having before starting therapy. The clinician’s job is to make sure you go in with realistic expectations and a plan that will hold up after the event passes.

Realistic expectations

We will not give you a number-on-a-scale promise on this page, and you should be suspicious of any platform that does. What we can say honestly is what the published literature on GLP-1 therapy describes in broad terms: meaningful changes in appetite and food preference within the first few weeks of titration, gradual weight change over months rather than days, and a strong influence of behavior, sleep, and stress on the magnitude and durability of the effect. Patients who view the medication as the floor of a behavior plan, rather than the ceiling of a magic intervention, are the ones who tend to be satisfied.

When the answer is “not a great fit”

Sometimes the clinician’s answer at the end of a first visit is no, or not yet. That is part of doing the work honestly. A patient who is currently struggling with binge-eating pathology may be better served by therapy first. A patient whose blood pressure or thyroid lab is far out of range may need to address that before adding another variable. A patient who simply does not meet the clinical thresholds may be redirected to behavioral support or another path. Telling someone no when the answer is no is not lost revenue. It is the practice.

The practical next step

Form’s 60-second eligibility quiz captures the inputs the clinician will use to make this assessment — BMI, history, medications, contraindications, current goals. It does not prescribe anything; only a licensed clinician can do that, after an actual telehealth visit. What it does do is give you and the clinician a shared starting point so the visit itself is spent on questions worth asking.